Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Oric Pharmaceuticals (ORIC) Interest & Investment Income (2019 - 2023)

Oric Pharmaceuticals filings provide 5 years of Interest & Investment Income readings, the most recent being $1.7 million for Q1 2023.

  • Quarterly Interest & Investment Income rose 1650.51% to $1.7 million in Q1 2023 from the year-ago period, while the trailing twelve-month figure was $3.0 million through Mar 2023, up 1588.2% year-over-year, with the annual reading at $2.6 million for FY2022, 1775.89% up from the prior year.
  • Interest & Investment Income hit $1.7 million in Q1 2023 for Oric Pharmaceuticals, up from $1.3 million in the prior quarter.
  • Across five years, Interest & Investment Income topped out at $1.7 million in Q1 2023 and bottomed at $10000.0 in Q3 2020.
  • Average Interest & Investment Income over 5 years is $328666.7, with a median of $99000.0 recorded in 2022.
  • The largest annual shift saw Interest & Investment Income crashed 97.9% in 2020 before it soared 3641.18% in 2022.
  • Oric Pharmaceuticals' Interest & Investment Income stood at $343000.0 in 2019, then crashed by 91.25% to $30000.0 in 2020, then grew by 13.33% to $34000.0 in 2021, then soared by 3641.18% to $1.3 million in 2022, then surged by 36.24% to $1.7 million in 2023.
  • Per Business Quant, the three most recent readings for ORIC's Interest & Investment Income are $1.7 million (Q1 2023), $1.3 million (Q4 2022), and $99000.0 (Q1 2022).